Sun Pharma S Breakthrough Treatment Gets Usfda Nod

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Sun Pharma's Breakthrough Treatment Gets USFDA Nod

ri-calendar-2-lineOct 6, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Sun Pharmaceutical Industries Ltd. received a significant boost as the United States Food and Drug Administration (USFDA) accepted its New Drug Application (NDA) for Deuruxolitinib, a promising drug targeting moderate to severe alopecia areata.

 

Alopecia areata, an autoimmune disorder leading to hair loss, currently has limited treatment options available. Sun Pharma submitted an 8mg twice daily dosage of Deuruxolitinib for USFDA review. This oral medication selectively inhibits Janus kinases JAK1 and JAK2, presenting a potential breakthrough for treating adult patients with alopecia areata.

 

Abhay Gandhi, CEO of North America Business at Sun Pharma, highlighted Deuruxolitinib's potential as a crucial treatment option for those struggling with this condition. Alongside Sun Pharma's Deuruxolitinib, Eli Lilly's Olumiant (Baricitinib) and Pfizer's Ritlecitinib (awaiting approval) are also promising treatments for alopecia areata.

 

The NDA filing is based on two Phase III trials encompassing over 1,200 patients across 135 clinical trial sites. These trials consistently demonstrated the high efficacy of Deuruxolitinib at the 8mg dose.

 

While Sun Pharma acquired the patent for Deuruxolitinib through its purchase of US-based Concert Pharmaceuticals for $576 million earlier this year, a US Appeals Court's ruling in favor of Incyte Corp's patent challenge could potentially impact Sun Pharma's launch plans for the drug.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions